Accessibility Menu

Nordicus Partners(OTC) ASNB

Current PriceN/A
Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2023)-59%
5 Year-86%
1 Year+10%
1 Month+18%
Nordicus Partners last closing stock price
MetricPriceDate
Last closeUSD 2.252026-07-23
Nordicus Partners stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-10%USD 2.502026-07-16
1 month+18.42%USD 1.902026-06-23
3 month-43.75%USD 4.002026-04-24
Year to date-55%USD 5.002025-12-31
1 year+9.76%USD 2.052025-07-22
3 year-70.78%USD 7.702023-07-17
5 year-85.83%USD 15.882021-07-23
Since inception-59.09%USD 5.502023-02-28

Nordicus Partners Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$4.55M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Feb 17, 2020

ASNB News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Nordicus Partners

Nordicus helps Nordic biotech firms develop new oral health medicines for U.S. patients. Its main projects target gum disease and oral lesions, aiming to improve dental care. The company supports early-stage research, making new treatments possible for people with unmet dental needs.

What’s in the Nordicus Toolbox?

  • Oral Health R&D: Develops new medicines for gum disease and oral lesions; 0% of revenue (pre-revenue).
  • Business Acceleration: Acquires and manages early-stage Nordic biotech firms; 0% of revenue.
  • Corporate Finance Services: Offers growth strategy, talent search, and capital raising for portfolio companies; 0% of revenue.
  • Minority Investment: Holds 4.99% in Mag Mile Capital, a real estate finance firm; not a core segment.

Growth Moves: Nordicus’ Recent Playbook

  • Acquired 95% of Orocidin A/S in May 2024; completed 100% buyout in November 2024.
  • Acquired 100% of Bio-Convert A/S in November 2024.
  • Expanded R&D focus to preclinical drug candidates for oral health in 2024-2025.
  • Raised $997,525 in new equity after June 2025 to support operations.

Nordicus: The Quirks That Count

Nordicus blends Nordic biotech innovation with U.S. business know-how. It specializes in early-stage drug development for oral health, using a portfolio approach to manage risk. The company’s structure allows it to quickly acquire, develop, and exit promising life sciences projects.

Five Things You Need to Know

  • Revenue was $0 in QQ2 2025, down 100% from QQ2 2024.
  • Operating expenses rose to $831,886 in QQ2 2025.
  • Net loss reached $1.2 million in QQ2 2025, up from $258,169 in QQ2 2024.
  • Cash balance was $8,418 as of June 30, 2025, with new funds raised post-quarter.

Bottom Line

Nordicus has shifted from a holding company to a focused oral health biotech accelerator. Its future depends on advancing early-stage medicines and securing new funding.

AI Generated • Apr 16, 2026

Industry

Capital Markets

Sector

Financials

CEO

Henrik Rouf

Website

www.nordicuspartners.com

Headquarters

Las Vegas, NV 89103, US

ASNB Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-6.20%

Return on Capital

-6.80%

Return on Assets

-5.30%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$4.05M

EBITDA

-$828.08K

Operating Cash Flow

-$4.32M

Capital Expenditure

-$17.76K

Free Cash Flow

-$4.34M

Cash & ST Invst.

$20.88K

Total Debt

$0.00

Nordicus Partners Performance Analysis

Nordicus Partners annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-03-31USD 0N/A
20242024-03-31USD 2,500N/A
20252025-03-31USD 5,000100.0%
20262026-03-31USD 0N/A
Nordicus Partners sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-06-30N/A
Q22025-09-30N/A
Q32025-12-31N/A
Q42026-03-31N/A
Nordicus Partners annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-03-31USD -14.274595.8%
20242024-03-31USD -0.29-98.0%
20252025-03-31USD -0.329.4%
20262026-03-31USD -0.22-29.9%
Nordicus Partners sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-06-3012.5%
Q22025-09-30-14.3%
Q32025-12-3112.5%
Q42026-03-31N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2025YOY CHG

Revenue

$0.00

-100.0%

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

11

N/A

Net Income

-$1.23M

+20.1%

EBITDA

$3.43K

-4.9%

Quarterly Fundamentals

Name
Q3 2025YOY CHG

Total Cash

$20.88K

+4.8%

Total Debt

$0.00

N/A

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-5.30%

N/A

Return on Invested Capital

-5.89%

N/A

Free Cash Flow

-$673.23K

+99.8%

Operating Cash Flow

-$675.08K

+99.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
GDVMGlobal Developments, Inc.
$0.01-1.59%
CDBTChina Dasheng Biotechnology Company
$0.10+0.00%
PGIDPeregrine Industries, Inc.
$0.00-60.00%
TOGITurnOnGreen, Inc
$0.02+3.30%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$92.32-0.08%
NOKNokia
$9.10-0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
ONDSOndas
$7.80-0.02%

Questions About ASNB

What is the current price of Nordicus Partners?

Nordicus Partners is trading at N/A per share.

What is the 52-week range for Nordicus Partners?

Over the past 52 weeks, Nordicus Partners has traded between N/A and N/A.

How much debt does Nordicus Partners have?

As of the most recent reporting period, Nordicus Partners reported total debt of $60.00K.

How much cash does Nordicus Partners have on hand?

Nordicus Partners reported $20.88K in cash and cash equivalents in its most recent financial results.

What is Nordicus Partners’s dividend yield?

Nordicus Partners does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services